Arvinas (NASDAQ: ARVN) Surges 17.66% on Strategic Shift to Early-Stage PROTACs, Regulatory Momentum

Arvinas (NASDAQ: ARVN) surged 17.66% in pre-market trading on November 19, 2025, driven by renewed investor confidence in its restructured pipeline and strategic focus on early-stage PROTAC degraders. The rally follows a Jefferies London Healthcare Conference presentation and accelerating regulatory momentum for its lead candidate, vepdegestrant.

The stock’s upward trajectory reflects a strategic pivot announced in Q3 2025, where Arvinas prioritized neurology and next-gen oncology programs—such as ARV-102 (LRRK2) and ARV-806 (KRAS G12D)—over later-stage oncology assets. The company also highlighted a $787.6 million cash runway extending into 2028, alongside cost-cutting measures including a 15% workforce reduction and a $100 million share repurchase program. These moves aim to streamline operations while maintaining flexibility for upcoming clinical milestones.

Vepdegestrant remains a pivotal catalyst, with the FDA’s PDUFA date set for June 5, 2026. The breast cancer drug, now being prepared for commercialization by a third party, could become the first PROTAC therapy to reach market if approved. Meanwhile, early-stage programs like ARV-393 (BCL6) and ARV-027 (SBMA) are advancing, supported by preclinical data showing strong target engagement and therapeutic potential.

Analyst sentiment has shifted cautiously optimistic, with price targets clustering around $15–$16. The recent rebound positions ARVN closer to the midpoint of its 52-week range ($5.90–$27.00), balancing near-term momentum against longer-term execution risks. Upcoming data from the ASH 2025 conference and Phase 1b trials in 2026 will be critical in validating the pipeline’s value proposition.